Co-designing Digital Ulcers Opportunities With Patients and Clinicians
Conditions: Scleroderma; Scleroderma Associated Digital Ulcer; Digital Ulcer Intervention: Other: No intervention Sponsors: King's College London; Royal Free Hospital NHS Foundation Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions: Systemic Sclerosis With Lung Involvement; Systemic Sclerosis; Interstitial Lung Disease Interventions: Drug: Mycophenolate Mofetil; Other: Placebo Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); McGill University; University of Calgary; St. Joseph's Healthcare Hamilton; Jewish General Hospital; Canadian Institutes of Health Research (CIHR); Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions: Idiopathic Pulmonary Fibrosis; Systemic Sclerosis With Lung Involvement Interventions: Drug: Vixarelimab; Drug: Placebo Sponsor: Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Co-designing Digital Ulcers Opportunities With Patients and Clinicians
Conditions: Scleroderma; Scleroderma Associated Digital Ulcer; Digital Ulcer Intervention: Other: No intervention Sponsors: King's College London; Royal Free Hospital NHS Foundation Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions: Systemic Sclerosis With Lung Involvement; Systemic Sclerosis; Interstitial Lung Disease Interventions: Drug: Mycophenolate Mofetil; Other: Placebo Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); McGill University; University of Calgary; St. Joseph's Healthcare Hamilton; Jewish General Hospital; Canadian Institutes of Health Research (CIHR); Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions: Idiopathic Pulmonary Fibrosis; Systemic Sclerosis With Lung Involvement Interventions: Drug: Vixarelimab; Drug: Placebo Sponsor: Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Co-designing Digital Ulcers Opportunities With Patients and Clinicians
Conditions: Scleroderma; Scleroderma Associated Digital Ulcer; Digital Ulcer Intervention: Other: No intervention Sponsors: King's College London; Royal Free Hospital NHS Foundation Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions: Systemic Sclerosis With Lung Involvement; Systemic Sclerosis; Interstitial Lung Disease Interventions: Drug: Mycophenolate Mofetil; Other: Placebo Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); McGill University; University of Calgary; St. Joseph's Healthcare Hamilton; Jewish General Hospital; Canadian Institutes of Health Research (CIHR); Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions: Idiopathic Pulmonary Fibrosis; Systemic Sclerosis With Lung Involvement Interventions: Drug: Vixarelimab; Drug: Placebo Sponsor: Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Co-designing Digital Ulcers Opportunities With Patients and Clinicians
Conditions: Scleroderma; Scleroderma Associated Digital Ulcer; Digital Ulcer Intervention: Other: No intervention Sponsors: King's College London; Royal Free Hospital NHS Foundation Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions: Systemic Sclerosis With Lung Involvement; Systemic Sclerosis; Interstitial Lung Disease Interventions: Drug: Mycophenolate Mofetil; Other: Placebo Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); McGill University; University of Calgary; St. Joseph's Healthcare Hamilton; Jewish General Hospital; Canadian Institutes of Health Research (CIHR); Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Conditions: Idiopathic Pulmonary Fibrosis; Systemic Sclerosis With Lung Involvement Interventions: Drug: Vixarelimab; Drug: Placebo Sponsor: Genentech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Co-designing Digital Ulcers Opportunities With Patients and Clinicians
Conditions: Scleroderma; Scleroderma Associated Digital Ulcer; Digital Ulcer Intervention: Other: No intervention Sponsors: King's College London; Royal Free Hospital NHS Foundation Trust Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
Conditions: Systemic Sclerosis With Lung Involvement; Systemic Sclerosis; Interstitial Lung Disease Interventions: Drug: Mycophenolate Mofetil; Other: Placebo Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); McGill University; University of Calgary; St. Joseph's Healthcare Hamilton; Jewish General Hospital; Canadian Institutes of Health Research (CIHR); Sclérodermie Québec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2023 Category: Research Source Type: clinical trials
Klotho and Mineral Bone Density in Systemic Sclerosis
Condition: Systemic Sclerosis Interventions: Other: Possible Klotho effects on SSc clinical conditions, namely skeletal, fibrotic and microangiopathic damage; Other: Evalution in healthy patients of bone mineral density, Klotho level and key bone-related cytokines Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2023 Category: Research Source Type: clinical trials
